A phase III randomized, double-blind, placebo-controlled trial of radium-223 dichloride in combination with abiraterone acetate and prednisone/prednisolone in the treatment of asymptomatic or mildly symptomatic chemotherapy-naïvepts with bone predominant metastatic castration-resistant prostate cancer (CRPC)

Project: Research

Project Details

Project Description

SERP Reference Number: HREC/14/SVH/67.
SSA Reference Number: SSA/15/MonH/83.
Monash Health HREC Ref: 15332X
Effective start/end date20/06/1919/06/24


  • clinical trial
  • prostate cancer
  • treatment efficacy
  • phase 3 study